Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan

Kenichi Harada, Masahiro Nozawa, Motohide Uemura, Katsunori Tatsugami, Takahiro Osawa, Kazutoshi Yamana, Go Kimura, Masato Fujisawa, Norio Nonomura, Masatoshi Eto, Nobuo Shinohara, Yoshihiko Tomita, Yukihiro Kondo, Kenya Ochi, Yoshio Anazawa, Hirotsugu Uemura

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.

Original languageEnglish
Pages (from-to)202-210
Number of pages9
JournalInternational Journal of Urology
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Renal Cell Carcinoma
Japan
Protein-Tyrosine Kinases
Phosphotransferases
Therapeutics
Sirolimus
Survival
Kidney Neoplasms
Medical Records
Cytokines

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. / Harada, Kenichi; Nozawa, Masahiro; Uemura, Motohide; Tatsugami, Katsunori; Osawa, Takahiro; Yamana, Kazutoshi; Kimura, Go; Fujisawa, Masato; Nonomura, Norio; Eto, Masatoshi; Shinohara, Nobuo; Tomita, Yoshihiko; Kondo, Yukihiro; Ochi, Kenya; Anazawa, Yoshio; Uemura, Hirotsugu.

In: International Journal of Urology, Vol. 26, No. 2, 01.02.2019, p. 202-210.

Research output: Contribution to journalArticle

Harada, K, Nozawa, M, Uemura, M, Tatsugami, K, Osawa, T, Yamana, K, Kimura, G, Fujisawa, M, Nonomura, N, Eto, M, Shinohara, N, Tomita, Y, Kondo, Y, Ochi, K, Anazawa, Y & Uemura, H 2019, 'Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan', International Journal of Urology, vol. 26, no. 2, pp. 202-210. https://doi.org/10.1111/iju.13830
Harada, Kenichi ; Nozawa, Masahiro ; Uemura, Motohide ; Tatsugami, Katsunori ; Osawa, Takahiro ; Yamana, Kazutoshi ; Kimura, Go ; Fujisawa, Masato ; Nonomura, Norio ; Eto, Masatoshi ; Shinohara, Nobuo ; Tomita, Yoshihiko ; Kondo, Yukihiro ; Ochi, Kenya ; Anazawa, Yoshio ; Uemura, Hirotsugu. / Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. In: International Journal of Urology. 2019 ; Vol. 26, No. 2. pp. 202-210.
@article{41d647641d9e4d4aa77bd6a3fc566c41,
title = "Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan",
abstract = "Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2{\%}), followed by mammalian target of rapamycin inhibitors (14.3{\%}) and cytokines (13.5{\%}). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8{\%}), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1{\%}) and cytokine–tyrosine kinase inhibitor (14.1{\%}). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.",
author = "Kenichi Harada and Masahiro Nozawa and Motohide Uemura and Katsunori Tatsugami and Takahiro Osawa and Kazutoshi Yamana and Go Kimura and Masato Fujisawa and Norio Nonomura and Masatoshi Eto and Nobuo Shinohara and Yoshihiko Tomita and Yukihiro Kondo and Kenya Ochi and Yoshio Anazawa and Hirotsugu Uemura",
year = "2019",
month = "2",
day = "1",
doi = "10.1111/iju.13830",
language = "English",
volume = "26",
pages = "202--210",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan

AU - Harada, Kenichi

AU - Nozawa, Masahiro

AU - Uemura, Motohide

AU - Tatsugami, Katsunori

AU - Osawa, Takahiro

AU - Yamana, Kazutoshi

AU - Kimura, Go

AU - Fujisawa, Masato

AU - Nonomura, Norio

AU - Eto, Masatoshi

AU - Shinohara, Nobuo

AU - Tomita, Yoshihiko

AU - Kondo, Yukihiro

AU - Ochi, Kenya

AU - Anazawa, Yoshio

AU - Uemura, Hirotsugu

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.

AB - Objectives: To clarify treatment patterns and outcomes for patients with unresectable or metastatic renal cell carcinoma in the molecular target therapy era in Japan. Methods: A multicenter, retrospective medical chart review study was carried out. Patients diagnosed with unresectable or metastatic renal cell carcinoma between January 2012 and August 2015 were enrolled. Data extracted from medical records included treatment duration, grade ≥3 adverse events, reason for discontinuation for each targeted therapy and survival data until August 2016. Results: Of 277 eligible patients, 266, 170 and 77 received first-, second- and third-line systemic treatment, respectively. Tyrosine kinase inhibitors were the most common first-line therapy (72.2%), followed by mammalian target of rapamycin inhibitors (14.3%) and cytokines (13.5%). Among 170 patients who received second-line treatment, tyrosine kinase inhibitor–tyrosine kinase inhibitor was the most common sequence (58.8%), followed by tyrosine kinase inhibitor–mammalian target of rapamycin inhibitor (14.1%) and cytokine–tyrosine kinase inhibitor (14.1%). With a median follow-up period of 19.8 months, median overall survival was not reached at 48 months. Patients who discontinued first-line tyrosine kinase inhibitors in <6 months showed poorer overall survival compared with patients who received first-line tyrosine kinase inhibitors for ≥6 months. Conclusions: The present analysis illustrates the contemporary treatment patterns and prognosis for patients with unresectable or metastatic renal cancer in a real-world setting in Japan. Tyrosine kinase inhibitor–tyrosine kinase inhibitor represents the most commonly used sequence. Shorter treatment duration of first-line tyrosine kinase inhibitors is associated with poorer prognosis, suggesting the need for better treatment options.

UR - http://www.scopus.com/inward/record.url?scp=85055260269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055260269&partnerID=8YFLogxK

U2 - 10.1111/iju.13830

DO - 10.1111/iju.13830

M3 - Article

C2 - 30345560

AN - SCOPUS:85055260269

VL - 26

SP - 202

EP - 210

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 2

ER -